Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Melanoma 2Sarcoma 1Ovarian Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Fallopian Tube Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Brenner Tumor 1

Interventions

Paclitaxel 25Carboplatin 22Taxes 16Bevacizumab 10Cisplatin 8Immunoglobulin G 7Disulfides 7Topotecan 3Platinum 3Docetaxel 31,2-diaminocyclohexaneplatinum II citrate 3paclitaxel poliglumex 2VTX-2337 2SS1(dsFv)PE38 2Peripheral Blood Stem Cell Transplantation 2Gemcitabine 2Filgrastim 2Etoposide 2Erlotinib Hydrochloride 2Chemotherapy, Adjuvant 2veliparib 1trioctyl phosphine oxide 1sargramostim 1pegfilgrastim 1liposomal doxorubicin 1emactuzumab 1elesclomol 1dexamethasone acetate 1dexamethasone 21-phosphate 1belinostat 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Brenner Tumor × elesclomol × Clear all
NCT00888615 2021-10-20

Elesclomol Sodium and Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

GOG Foundation

Phase 2 Completed
58 enrolled 13 charts
Gynecologic

Brenner Tumor, Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡